Furthermore, the antitumor efficacy of IR towards CT26 colon cancer models was greatly compromised in mice deficient for CD8α+ DCs, indicating the necessity for specialized cross-presenting DC subtypes for ideal tumor control using IR [13]. Here, CD8A is linked to neoplasm.